Another key objective is to find vaccines that can provide longer-lasting protection, so people do not need to have a booster shot every ... of the technology in COVID-19 vaccines, the NIAID ...

Nov 12 (Reuters) - Novavax (NVAX.O), opens new tab cut its annual revenue forecast on Tuesday, citing lower-than-expected ...

The Gaithersburg biotech is preparing to turn over sales activity for its only product to its commercial partner. Novavax Inc. has made a smaller splash in the U.S. Covid-19 vaccine market than it ...

Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for review the resubmission of the supplemental Biologics License ...

The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

Sanofi (Symbol: SNY) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors.

Health agencies, counties and state officials have been resisting efforts to provide booster jabs to Americans this fall.

Booster doses of the original monovalent COVID-19 vaccine are associated with lower incidence of symptoms in health care personnel 6 weeks postinfection.

Development of the coronavirus disease 2019 (COVID-19) vaccine has been key to countering the pandemic caused by severe acute ...

Florida Gov. Ron DeSantis is advising against the use of the new COVID-19 booster for people under the age of 65, even as infections tick upward in the U.S. A NIH-sponsored clinical trial has ...

RNA vaccines saved lives during the COVID-19 pandemic, but older people had less of an immune response to the vaccines than ...

Sanofi and GlaxoSmithKline are restarting clinical development of their COVID-19 vaccine, which was delayed after hitting a snag late last year. In December interim phase 1/2 trial results showed ...